ENTRECTINIB for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 47 adverse event reports in the FDA FAERS database where ENTRECTINIB was used for Neoplasm malignant.
Most Reported Side Effects for ENTRECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Dizziness | 143 | 9.6% | 13 | 25 |
| Off label use | 137 | 9.2% | 20 | 10 |
| Death | 126 | 8.5% | 125 | 6 |
| Disease progression | 105 | 7.0% | 38 | 15 |
| Taste disorder | 68 | 4.6% | 7 | 9 |
| No adverse event | 65 | 4.4% | 0 | 1 |
| Constipation | 60 | 4.0% | 3 | 9 |
| Fatigue | 60 | 4.0% | 6 | 11 |
| Drug ineffective | 58 | 3.9% | 13 | 4 |
| Blood creatinine increased | 57 | 3.8% | 7 | 17 |
| Nausea | 56 | 3.8% | 3 | 11 |
| Renal impairment | 53 | 3.6% | 5 | 8 |
| Diarrhoea | 52 | 3.5% | 7 | 15 |
| Weight increased | 51 | 3.4% | 3 | 9 |
| Cardiac failure | 45 | 3.0% | 11 | 24 |
Other Indications for ENTRECTINIB
Non-small cell lung cancer (412)
Lung neoplasm malignant (339)
Product used for unknown indication (196)
Neoplasm (56)
Lung adenocarcinoma (54)
Non-small cell lung cancer metastatic (41)
Metastases to central nervous system (25)
Bronchial carcinoma (23)
Pancreatic carcinoma metastatic (18)
Lung adenocarcinoma stage iv (16)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)